Bristol-Myers Squibb Company (NYSE:BMY) and QIAGEN (NASDAQ:QGEN;
Frankfurt Prime Standard:QIA) have signed an agreement to explore
the use of next-generation sequencing (NGS) technology to develop
gene expression profiles (GEPs) as predictive or prognostic tools
for use with Bristol-Myers Squibb novel immuno-oncology (I-O)
therapies in cancer treatment. This will leverage the combination
of Bristol-Myers Squibb’s portfolio of I-O therapies with QIAGEN’s
proven track record in developing and commercializing companion and
complementary diagnostics as well as QIAGEN’s portfolio of NGS
technologies. I-O therapies offer a novel way to treat cancer by
using drugs to target the body’s immune system to help fight
cancer.
QIAGEN and Bristol-Myers Squibb intend to develop GEPs for
several Bristol-Myers Squibb I-O molecules under the initial
agreement. The companies also plan to enter into a further
agreement to develop diagnostic products using the jointly
developed GEPs and to expand the use of NGS technology with other
Bristol-Myers Squibb I-O therapies.
“Greater precision in the treatment of cancer may enable faster
decision making to identify which patient populations are most
likely to derive benefit from our immuno-oncology agents,” said
Fouad Namouni, M.D., head of Development, Oncology, Bristol-Myers
Squibb. “We believe working with QIAGEN will help develop better
diagnostic tools to target the most appropriate immunotherapies
across a number of different tumor types.”
“We are very pleased to work with Bristol-Myers Squibb to
potentially create what could be the first-ever NGS-based companion
or complementary diagnostic to provide key insights for
personalized decision-making in the rapidly expanding area of
immuno-oncology,” said Peer M. Schatz, Chief Executive Officer of
QIAGEN. “Our teams at QIAGEN are looking forward to working with
Bristol-Myers Squibb to leverage the power of NGS technology to
potentially improve outcomes for patients.”
QIAGEN and Bristol-Myers Squibb have been partnering since 2009.
A key milestone in this partnership was the FDA approval of the
Therascreen KRAS companion/complementary diagnostic assay in
2012.
Bristol-Myers Squibb & Immuno-Oncology: Advancing
Oncology Research
At Bristol-Myers Squibb, patients are at the center of
everything we do. Our vision for the future of cancer care is
focused on researching and developing transformational
Immuno-Oncology (I-O) medicines for hard-to-treat cancers that
could potentially improve outcomes for these patients.
We are leading the scientific understanding of I-O through our
extensive portfolio of investigational compounds and approved
agents. Our differentiated clinical development program is studying
broad patient populations across more than 50 types of cancers with
14 clinical-stage molecules designed to target different immune
system pathways. Our deep expertise and innovative clinical trial
designs position us to advance I-O/I-O, I-O/chemotherapy,
I-O/targeted therapies and I-O/radiation therapies across multiple
tumors and potentially deliver the next wave of therapies with a
sense of urgency. We also continue to pioneer research that will
help facilitate a deeper understanding of the role of immune
biomarkers and how patients’ individual tumor biology can be used
as a guide for treatment decisions throughout their journey.
We understand making the promise of I-O a reality for the many
patients who may benefit from these therapies requires not only
innovation on our part but also close collaboration with leading
experts in the field. Our partnerships with academia, government,
advocacy and biotech companies support our collective goal of
providing new treatment options to advance the standards of
clinical practice.
QIAGEN GeneReader NGS System
The GeneReader NGS System provides the first true Sample to
Insight NGS workflow for laboratories worldwide – and increasingly
also pharmaceutical companies – to take advantage of the power of
NGS technology. The system’s integrated bioinformatics for analysis
and interpretation of NGS data, as well as a family of gene panels
under the GeneRead QIAact brand, enable laboratories to identify
gene variations linked to cancers and to deliver actionable
molecular insights. The capabilities of this unique system also
include high-sensitivity detection in liquid biopsy samples,
compatibility with the QIAsymphony automation platform for
high-throughput sample processing, and software integration with
leading Laboratory Information Management Systems (LIMS). The
current version of the GeneReader NGS System is available in the
United States for research use only.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, YouTube and Facebook.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare),
Applied Testing (forensics, veterinary testing and food safety),
Pharma (pharma and biotech companies) and Academia (life sciences
research). As of March 31, 2017, QIAGEN employed approximately
4,700 people in over 35 locations worldwide. Further information
can be found at http://www.qiagen.com.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are
based on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking
statement can be guaranteed. Among other risks, there can be no
guarantee that the project will proceed as planned or that the
assays or diagnostics described in this release will be
successfully developed or approved for any of the indications
described in this release. Forward-looking statements in this
press release should be evaluated together with the many
uncertainties that affect Bristol-Myers Squibb's business,
particularly those identified in the cautionary factors discussion
in Bristol-Myers Squibb's Annual Report on Form 10-K for the year
ended December 31, 2016 in our Quarterly Reports on Form 10-Q and
our Current Reports on Form 8-K. Bristol-Myers Squibb
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
QIAGEN Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to,
the U.S. Securities and Exchange Commission (SEC).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170603005035/en/
BRISTOL-MYERS SQUIBBInvestorsTim Power,
609-252-7509timothy.power@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.comorMediaLisa McCormick
Lavery, 609-252-7602lisa.mccormicklavery@bms.comorKen Dominski,
609-252-5251ken.dominski@bms.comorQIAGENInvestor
RelationsJohn Gilardi, +49 2103 29
11711ir@QIAGEN.comorPublic RelationsDr. Thomas Theuringer,
+49 2103 29 11826pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Mar 2023 to Mar 2024